No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
www.ssygroup.com.hkNo one on the platform currently holds 2005.HK.
No tracked institution reports a position in 2005.HK as of their last filing.
No one on the platform has traded 2005.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.6% | 11.9% | 13.7% | — | — | — |
| Rev. Growth % | -27.8% | -0.5% | ||||
| Profit Margin % | 11.3% | 16.4% | 18.5% | |||
| Free Cash Flow Margin % | 7.2% | 4.4% | 6.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.7B | +10.7% | $0.20 | $0.19–$0.21 | — | 2 |
| 2027 | $5.2B | +10.5% | $0.23 | $0.22–$0.25 | — | 2 |
| 2028 | $5.7B | +8.9% | $0.27 | $0.25–$0.29 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2005.HKSSY Group Limited | $2.70 | +2.08% | $7.8B | — |
| 0570.HKChina Traditional Chinese Medicine Holdings Co. Limited | $1.27 | +1.19% | $6.4B | — |
| 0719.HKShandong Xinhua Pharmaceutical Company Limited | $5.42 | -1.36% | $8.2B | — |
| 1672.HKAscletis Pharma Inc. | $8.94 | -0.67% | $9.4B | — |
| 1681.HKConsun Pharmaceutical Group Limited |
| $13.26 |
| -0.15% |
| $11.1B |
| — |
| 2609.HKBayzed Health Group, Inc. | $2.92 | +1.39% | $3.9B | — |
| 2616.HKCStone Pharmaceuticals | $5.95 | -0.50% | $9.5B | — |
Source: Financial Modeling Prep · peers by sector/industry